Vaxzevria ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症1

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003277-55-AT
(EUCTR)
01/09/202127/07/2021COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CFCOVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF - CAR-CF COVID-19 vaccine Antibody response from natural infection or after vaccination in patients with Cystic Fibrosis (CF)
MedDRA version: 20.0;Level: LLT;Classification code 10021433;Term: Immunization;System Organ Class: 100000004865
MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify
Trade Name: Comirnaty concentrate for dispersion for injection
Product Name: Comirnaty
INN or Proposed INN: Tozinameran
Other descriptive name: COVID-19 mRNA vaccine (nucleoside-modified)
Trade Name: Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S
Product Name: Vaxzevria
INN or Proposed INN: COVID-19 Vaccine (ChAdOx1-S [recombinant])
Other descriptive name: COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)
Trade Name: COVID-19 Vaccine Moderna dispersion for injection
Product Name: COVID-19 Vaccine Moderna
INN or Proposed INN: Elasomeran
Other descriptive name: COVID-19 mRNA vaccine Moderna (CX-024414)
Trade Name: COVID-19 Vaccine Janssen suspension for injection
Product Name: COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant])
INN or Proposed INN: COVID-19 vaccine (Ad26.COV2-S [recombinant])
Other descriptive name: Ad26.COV2-S.02
Medical University of Innsbruck, University Clinic for Pediatrics IIINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
5000Phase 4United States;European Union;Canada;Ireland;Austria;United Kingdom